ResMed | RMD - Sales Revenues


ResMed reported $1.4B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Ansell USD 1.03B 192.2M Dec/2025
Artivion USD 115.99M 2.6M Dec/2025
AtriCure USD 141.2M 700K Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Cochlear AUD 1.18B 590.35M Dec/2025
Cooper Companies USD 1.08B 57.4M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Dexcom USD 1.19B 70M Mar/2026
Edwards Lifesciences USD 1.65B 80M Mar/2026
Fisher Paykel Healthcare NZD 1.24B 137.8M Jun/2026
Globus Medical USD 759.85M 66.55M Mar/2026
Haemonetics USD 346M 7.03M Mar/2026
Idexx Laboratories USD 1.14B 50M Mar/2026
Inogen USD 74.93M 504K Sep/2024
Insulet USD 761.7M 22.1M Mar/2026
Integra LifeSciences USD 391.9M 43M Mar/2026
Intuitive Surgical USD 2.89B 120M Jun/2026
Medtronic USD 9.8B 800M Mar/2026
Philips EUR 3.91B 1.19B Mar/2026
Ramsay Health Care AUD 9.34B 82.2M Dec/2025
ResMed USD 1.4B 0 Mar/2026
Sigma Healthcare AUD 1.68B 188.65M Dec/2024
Sonic Healthcare AUD 5.45B 470M Dec/2025
Steris USD 1.59B 90M Mar/2026
Teleflex USD 548.3M 20.68M Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026